XT
KTTA icon

XTX Topco’s Pasithea Therapeutics KTTA Stock Holding History

XTX Topco’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Buy
33,751
+12,968
+62% +$10.8K ﹤0.01% 3495
2025
Q4 		$26.8K Sell
20,783
-13,575
-40% -$11.9K ﹤0.01% 2993
2025
Q3 		$24.7K Buy
+34,358
New +$25.1K ﹤0.01% 2290
2023
Q4 		– Sell
-536
Closed -$5.14K – 1862
2023
Q3 		$5.14K Buy
+536
New +$5.87K ﹤0.01% 1462

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's KTTA Position: Q1 2026 in Review

XTX Topco increased its Pasithea Therapeutics (KTTA) stake by 62% in Q1 2026, buying an estimated $10.8K and bringing the position to 33,751 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

XTX Topco first reported a position in KTTA in Q3 2023 and has held it in 4 quarters since. The position peaked at $26.8K in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • XTX Topco held 33,751 shares of Pasithea Therapeutics worth $25K as of Q1 2026.
  • XTX Topco bought 12,968 Pasithea Therapeutics shares in Q1 2026, an estimated $10.8K.
  • Pasithea Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3495 holding.
  • XTX Topco first reported a position in Pasithea Therapeutics in Q3 2023 and has held it in 4 quarters since.
  • XTX Topco's Pasithea Therapeutics position peaked at $26.8K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.